Home > Publications database > GPU-accelerated FREDopt package for simultaneous dose and LETdproton radiotherapy plan optimization via superiorization methods. > print

001     302266
005     20250831022350.0
024 7 _ |a 10.1088/1361-6560/ade841
|2 doi
024 7 _ |a pmid:40562074
|2 pmid
024 7 _ |a 0031-9155
|2 ISSN
024 7 _ |a 1361-6560
|2 ISSN
024 7 _ |a altmetric:179477384
|2 altmetric
037 _ _ |a DKFZ-2025-01292
041 _ _ |a English
082 _ _ |a 530
100 1 _ |a Borys, Damian
|0 0000-0003-0229-2601
|b 0
245 _ _ |a GPU-accelerated FREDopt package for simultaneous dose and LETdproton radiotherapy plan optimization via superiorization methods.
260 _ _ |a Bristol
|c 2025
|b IOP Publ.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756456548_12783
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 70(15), 155011
520 _ _ |a This study presents FREDopt, a newly developed GPU-accelerated open-source optimization software for simultaneous proton dose and dose-averaged LET (LETd) optimization in IMPT treatment planning. FREDopt was implemented entirely in Python, leveraging CuPy for GPU acceleration and incorporating fast Monte Carlo (MC) simulations from the FRED code. The treatment plan optimization workflow includes pre-optimization and optimization, the latter equipped with a novel superiorization of feasibility-seeking algorithms. Feasibility-seeking requires finding a point that satisfies prescribed constraints. Superiorization interlaces computational perturbations into iterative feasibility-seeking steps to steer them toward a superior feasible point, replacing the need for costly full-fledged constrained optimization. The method was validated on two treatment plans of patients treated in a clinical proton therapy center, with dose and LETd distributions compared before and after reoptimization. Simultaneous dose and LETd optimization using FREDopt led to a substantial reduction of LETd and (dose)×(LETd) in organs at risk (OARs) while preserving target dose conformity. Computational performance evaluation showed execution times of 14-50 minutes, depending on the algorithm and target volume size-satisfactory for clinical and research applications while enabling further development of the well-tested, documented open-source software.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a feasibility seeking
|2 Other
650 _ 7 |a linear energy transfer (LET)
|2 Other
650 _ 7 |a proton therapy
|2 Other
650 _ 7 |a radiation therapy
|2 Other
650 _ 7 |a superiorization
|2 Other
650 _ 7 |a treatment plan optimization
|2 Other
700 1 _ |a Gajewski, Jan
|0 0000-0002-7416-5145
|b 1
700 1 _ |a Becher, Tobias
|0 P:(DE-He78)49b8eff4c466e1497028f0ad44747355
|b 2
|u dkfz
700 1 _ |a Censor, Yair
|0 0000-0003-2247-818X
|b 3
700 1 _ |a Kopec, Renata
|0 0000-0002-0919-9859
|b 4
700 1 _ |a Rydygier, Marzena
|0 0000-0003-4102-858X
|b 5
700 1 _ |a Schiavi, Angelo
|b 6
700 1 _ |a Skóra, Tomasz
|0 0000-0001-6322-0615
|b 7
700 1 _ |a Spaleniak, Anna
|0 0009-0002-6811-3100
|b 8
700 1 _ |a Wahl, Niklas
|0 P:(DE-He78)dfd5aaf608015baaaed0a15b473f1336
|b 9
|u dkfz
700 1 _ |a Wochnik, Agnieszka
|0 0000-0002-7848-1145
|b 10
700 1 _ |a Rucinski, Antoni
|0 0000-0002-5815-4606
|b 11
773 _ _ |a 10.1088/1361-6560/ade841
|0 PERI:(DE-600)1473501-5
|n 15
|p 155011
|t Physics in medicine and biology
|v 70
|y 2025
|x 0031-9155
909 C O |p VDB
|o oai:inrepo02.dkfz.de:302266
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)49b8eff4c466e1497028f0ad44747355
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)dfd5aaf608015baaaed0a15b473f1336
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2025
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2024-12-27
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHYS MED BIOL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-27
920 1 _ |0 I:(DE-He78)E040-20160331
|k E040
|l E040 Med. Physik in der Strahlentherapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E040-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21